Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 1.00 |
| ▸ | PTGIR | P43119 | 1/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466694 | 0.96 | PTGDR2 (0.93) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1466212 | 0.91 | PTGDR2 (0.84) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1466718 | 0.88 | PTGDR2 (0.78) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1466738 | 0.87 | PTGDR2 (0.77) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1466406 | 0.86 | PTGDR2 (1.00) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1466910 | 0.85 | PTGDR2 (1.00) | PTGDR2PTGIRPTGDR | |
| SCHEMBL3716457 | 0.84 | PTGDR2 (0.72) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1466737 | 0.83 | PTGDR2 (0.94) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1466161 | 0.83 | PTGDR2 (0.71) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1466111 | 0.83 | PTGDR2 (0.71) | PTGDR2PTGIRPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246030-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LTD (GB) | 2015-09-03 | — | — | US | disclosed |
| US-20150246030-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LTD (GB) | 2015-09-03 | — | — | US | disclosed |
| US-20150246030-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LTD (GB) | 2015-09-03 | — | — | US | disclosed |
| US-8980927-B2 | Compounds having CRTH2 antagonist activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | disclosed |
| US-8980927-B2 | Compounds having CRTH2 antagonist activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | disclosed |
| US-8980927-B2 | Compounds having CRTH2 antagonist activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | disclosed |
| US-20140039012-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-20140039012-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-20140039012-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-8563536-B2 | Compounds having CRTH2 antagonist activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-20100266535-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| US-7750027-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-7750027-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-7750027-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-20100063103-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063103-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063103-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| WO-2009090414-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186923-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186923-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039012-A1 | Compounds Having CRTH2 Antagonist Activity | NR3C2, HRH2, NR2C2 | PTGDR2 214/4885PTGIR 1320/4885PTGDR 386/4885 |
| US-20100266535-A1 | Compounds Having CRTH2 Antagonist Activity | NR3C2, HRH2, NR2C2 | PTGDR2 214/4885PTGIR 1320/4885PTGDR 386/4885 |
| US-20090186923-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, HRH4, NR2C2 | PTGDR2 100/4885PTGIR 887/4885PTGDR 195/4885 |
| US-20150246030-A1 | Compounds Having CRTH2 Antagonist Activity | NR3C2, HRH2, NR2C2 | PTGDR2 218/4885PTGIR 1323/4885PTGDR 386/4885 |
| US-20100063103-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, NR3C2, HRH4 | PTGDR2 233/4885PTGIR 1326/4885PTGDR 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.